| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | POLR3A |
| Uniprot No | O14802 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 392-632aa |
| 氨基酸序列 | FPEKVNKANINFLRKLVQNGPEVHPGANFIQQRHTQMKRFLKYGNREKMAQELKYGDIVERHLIDGDVVLFNRQPSLHKLSIMAHLARVKPHRTFRFNECVCTPYNADFDGDEMNLHLPQTEEAKAEALVLMGTKANLVTPRNGEPLIAAIQDFLTGAYLLTLKDTFFDRAKACQIIASILVGKDEKIKVRLPPPTILKPVTLWTGKQIFSVILRPSDDNPVRANLRTKGKQYCGKGEDLC |
| 预测分子量 | 31.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于POLR3A重组蛋白的示例参考文献(文献为假设性举例，建议通过学术数据库验证真实性)：
---
1. **标题**: "Structural Insights into Human RNA Polymerase III Subunit POLR3A"
**作者**: Smith A, et al.
**摘要**: 本研究通过重组表达人源POLR3A蛋白，利用X射线晶体学解析其三维结构，揭示了其与RNA聚合酶III复合物中其他亚基的相互作用界面，为理解其转录调控机制提供结构基础。
2. **标题**: "Recombinant POLR3A Facilitates In Vitro Transcription Assays in Leukodystrophy Models"
**作者**: Lee C, et al.
**摘要**: 开发了重组POLR3A蛋白的高效表达纯化系统，并在体外转录实验中证明其功能缺失与脑白质病变相关突变的关联性，为疾病机制研究提供工具。
3. **标题**: "Functional Characterization of POLR3A Mutants Using Recombinant Protein Systems"
**作者**: Garcia-Ruiz S, et al.
**摘要**: 通过重组技术构建多种POLR3A突变体，分析其酶活性和稳定性，发现特定错义突变导致RNA聚合酶III功能异常，与遗传性神经退行性疾病相关。
---
**备注**：以上为模拟示例，实际文献需通过PubMed、Web of Science等平台以关键词“POLR3A recombinant”或“POLR3A expression”检索获取。
POLR3A, a critical subunit of RNA polymerase III (Pol III), is essential for synthesizing small non-coding RNAs, including transfer RNAs (tRNAs), 5S ribosomal RNA (5S rRNA), and other regulatory RNAs vital for protein synthesis and cellular homeostasis. Encoded by the *POLR3A* gene, this protein forms the catalytic core of Pol III alongside POLR3B, enabling DNA-dependent RNA transcription. Structurally, POLR3A contains conserved domains for DNA binding, RNA synthesis, and interactions with transcription factors, making it indispensable for proper Pol III assembly and function.
Recombinant POLR3A protein is produced using biotechnological platforms, such as bacterial (e.g., *E. coli*) or eukaryotic (e.g., mammalian or insect cell) expression systems, followed by affinity chromatography purification. This engineered protein retains enzymatic activity and structural integrity, allowing researchers to study Pol III mechanisms in vitro. Applications include investigating transcription regulation, RNA processing, and interactions with cofactors or inhibitors. Recombinant POLR3A also aids in structural studies (e.g., X-ray crystallography or cryo-EM) to map functional domains or mutation impacts.
Mutations in *POLR3A* are linked to severe neurodevelopmental disorders, including hypomyelinating leukodystrophy (HLD7) and cerebellar atrophy, highlighting its role in neuronal health. Recombinant variants help dissect how specific mutations impair Pol III activity, leading to RNA dysregulation and disease. Additionally, this tool supports drug screening for therapies targeting Pol III dysfunction. By enabling precise biochemical and functional analyses, recombinant POLR3A advances our understanding of transcriptional regulation and its implications in both basic biology and disease pathology.
×
